🔍

APLLTD - Alembic Pharma

📊 NSE: APLLTD 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:07

📢 Recent Corporate Announcements

Alembic Pharma Schedules Q4 & FY26 Earnings Conference Call for May 15, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 29 Apr 2026, 05:08 PM

Alembic Pharmaceuticals Limited has announced its post-results conference call for Friday, May 15, 2026, at 5:00 PM IST. The call aims to discuss the company's audited financial results for the fourth quarter (Q4 FY26) and the full fiscal year 2026. Key management personnel, including Managing Directors Pranav Amin and Shaunak Amin, along with CFO G. Krishnan, will lead the discussion. This is a routine but essential event for institutional investors to gain insights into the company's annual performance.

Conference call scheduled for May 15, 2026, at 5:00 P.M. IST to discuss Q4 and FY26 results.
Senior management including MDs Pranav Amin and Shaunak Amin will be present.
The call will address audited financial performance for the full fiscal year 2026.
Universal access numbers and international toll-free lines have been provided for global participation.

💡 Investors should monitor the earnings release on or before May 15 for financial performance metrics and listen to the call for management's FY27 outlook.

Alembic Pharmaceuticals Reports Demise of Resident Director Saibal Mukherjee

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 27 Apr 2026, 12:23 PM

Alembic Pharmaceuticals Limited has informed the stock exchanges of the sudden demise of Mr. Saibal Mukherjee on April 26, 2026. Mr. Mukherjee served as the Resident Director for the company's Delhi Office and was classified as Senior Management Personnel. Having joined the organization in 2014, he had a tenure of approximately 12 years with the firm. The company has expressed that his passing is an irreparable loss to the organization.

Demise of Mr. Saibal Mukherjee, Resident Director (Delhi Office), occurred on April 26, 2026
Mr. Mukherjee was a long-term employee who joined the company in 2014
The disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015
The event is classified as a change in Senior Management Personnel due to death

💡 This is a routine regulatory disclosure regarding a loss in senior management; no immediate impact on business operations or stock performance is expected. Investors should continue to hold as per their existing strategy.

Alembic Pharma Incorporates Wholly-Owned Subsidiary in Germany with EUR 25,000 Share Capital

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 23 Apr 2026, 01:17 PM

Alembic Pharmaceuticals has announced the incorporation of a 100% wholly-owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany. The new entity is established with an initial share capital of EUR 25,000, consisting of 25,000 shares at EUR 1.00 each. This strategic move is designed to explore new business opportunities and establish a direct presence for the promotion, sale, and distribution of pharmaceutical products in the German market. As a newly formed entity, it currently has nil turnover and is yet to commence commercial operations.

Incorporation of 100% wholly-owned subsidiary 'Alembic Pharmaceuticals GmbH' in Germany.
Initial share capital set at EUR 25,000 divided into 25,000 shares of EUR 1.00 each.
Objective is to promote, sell, and distribute pharmaceutical products in the European geography.
The entity is a fresh incorporation with zero turnover as of the announcement date.

💡 Investors should view this as a positive long-term strategic move to strengthen the company's footprint in the European market. Monitor future updates regarding product registrations and revenue contributions from this new German entity.

Alembic Pharma Receives USFDA Final Approval for Methotrexate Injection

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 16 Apr 2026, 11:17 AM

Alembic Pharmaceuticals has received final USFDA approval for its Methotrexate Injection USP, which is therapeutically equivalent to Hospira's reference drug. The injection is a folate analog metabolic inhibitor used to treat various cancers, rheumatoid arthritis, and severe psoriasis. This approval marks a significant addition to Alembic's US portfolio, targeting both oncology and autoimmune segments. With this, the company's cumulative USFDA approvals have reached 236, including 218 final approvals.

Received final USFDA approval for Methotrexate Injection USP in 50 mg/2 mL and 1g/40 mL strengths
Product is indicated for multiple neoplastic diseases including Leukemia, Breast Cancer, and Head/Neck Cancer
Also approved for treating rheumatoid arthritis and severe psoriasis
Cumulative USFDA approvals now stand at 236 (218 final and 18 tentative approvals)

💡 This approval strengthens Alembic's US generic pipeline in high-value therapeutic areas like oncology and immunology. Investors should monitor the company's commercial launch timeline and market share gains in these segments.

Alembic Pharmaceuticals Submits SEBI Regulation 74(5) Compliance Certificate for Q4 FY2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Apr 2026, 06:11 PM

Alembic Pharmaceuticals has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms that all securities received for dematerialization during the quarter ended March 31, 2026, were processed according to regulatory timelines. It verifies that physical certificates were mutilated and cancelled after the name of the depositories was substituted in the register of members. This is a standard administrative filing ensuring the integrity of the company's shareholding records.

Compliance certificate submitted for the quarter ended March 31, 2026.
Issued by Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
Confirms dematerialization requests were processed and listed on stock exchanges within prescribed timelines.
Verification and cancellation of physical security certificates completed as per SEBI norms.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming financial results for material performance indicators.

Alembic Pharma Re-appoints Pranav Amin as Managing Director for 5-Year Term

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 01 Apr 2026, 06:41 PM

Alembic Pharmaceuticals has officially implemented the re-appointment of Mr. Pranav Amin as Managing Director, effective April 1, 2026. This follows the shareholder approval previously granted during the 15th Annual General Meeting held in August 2025. Mr. Amin, who leads the company's International Business, will serve a five-year term and is not liable to retire by rotation. The move ensures leadership continuity as the company focuses on international expansion and research-driven growth.

Mr. Pranav Amin re-appointed as Managing Director for a 5-year term starting April 1, 2026.
The appointment was previously approved by shareholders at the 15th AGM on August 5, 2025.
Mr. Amin is responsible for the International Business division, focusing on global R&D and manufacturing.
The appointee is not liable to retire by rotation and is not debarred by any SEBI order.
Mr. Amin is part of the promoter family, being the son of Chairman Chirayu Amin.

💡 Investors should view this as a routine management continuity event that maintains the current strategic direction of the company's international operations. No immediate portfolio action is required based solely on this announcement.

Alembic Pharma: Chirayu Amin Appointed Executive Chairman for 5 Years; Steps Down as CEO

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 01 Apr 2026, 06:38 PM

Alembic Pharmaceuticals has announced that Mr. Chirayu Amin has transitioned to the role of Executive Chairman for a five-year term starting April 1, 2026. He has simultaneously relinquished his position as the Chief Executive Officer (CEO) following the completion of his previous tenure. This move, which was approved by shareholders in August 2025, ensures leadership stability within the promoter family. Mr. Amin is the father of the company's current Managing Directors, Pranav and Shaunak Amin, indicating a clear succession and continuity plan.

Mr. Chirayu Amin appointed as Executive Chairman for a 5-year term effective April 1, 2026.
Relinquished the position of Chief Executive Officer (CEO) as of March 31, 2026.
The transition was previously approved by shareholders at the 15th AGM held on August 5, 2025.
Mr. Amin will not be liable to retire by rotation during his new tenure as Executive Chairman.

💡 This is a planned leadership transition that ensures continuity within the promoter-led management. Investors should view this as a routine administrative update with no immediate impact on the company's operational strategy.

Alembic Pharma Re-appoints Pranav Amin as Managing Director for 5-Year Term

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 01 Apr 2026, 06:25 PM

Alembic Pharmaceuticals has officially re-appointed Mr. Pranav Amin as Managing Director for a five-year term, effective from April 1, 2026. This move follows the shareholder approval previously granted at the 15th Annual General Meeting in August 2025. Mr. Amin, who heads the International Business, has been a key driver of the company's global expansion and R&D-led growth. The re-appointment ensures leadership continuity in critical business segments for the next half-decade.

Re-appointment of Mr. Pranav Amin as Managing Director for a 5-year tenure starting April 1, 2026.
The appointee is not liable to retire by rotation during this term.
Mr. Amin leads the International Business division, focusing on R&D and high-quality manufacturing.
The appointment was ratified by shareholders during the 15th AGM held on August 5, 2025.

💡 Investors should view this as a positive sign of management stability and continuity in the company's international growth strategy. No immediate portfolio action is required as this is a planned leadership extension.

Alembic Pharma Appoints Rajkumar Baheti as Non-Executive Director w.e.f. April 1, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 01 Apr 2026, 02:11 PM

Alembic Pharmaceuticals has appointed Mr. Rajkumar Baheti as a Non-Executive Non-Independent Director effective April 1, 2026. The appointment was approved by shareholders via a Postal Ballot on March 31, 2026. Mr. Baheti is a highly experienced professional with over 44 years of expertise in corporate finance, financial governance, and regulatory compliance. He holds fellow memberships in both the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India.

Appointment of Mr. Rajkumar Baheti as Non-Executive Non-Independent Director effective April 1, 2026
Appointee brings 44 years of extensive experience in finance and corporate governance
Shareholder approval secured via Postal Ballot on March 31, 2026
Mr. Baheti is a fellow member of both ICAI and ICSI

💡 This is a routine management update that strengthens the board's financial oversight. No immediate action is required as this does not impact the company's core operations or financial guidance.

Alembic Pharma: Head of Formulation Business Development Nilesh Wadhwa Resigns

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 31 Mar 2026, 08:57 PM

Alembic Pharmaceuticals Limited has announced the resignation of Mr. Nilesh Wadhwa, who served as the Head of Formulation Business Development. The resignation was effective as of the close of business hours on March 31, 2026. As a Senior Management Personnel, his departure marks a change in the leadership responsible for the company's formulation growth strategy. The company has complied with SEBI Regulation 30 by disclosing this management transition to the exchanges.

Mr. Nilesh Wadhwa resigned from his position as Head – Formulation Business Development.
The resignation is effective from March 31, 2026, after the closure of business hours.
The disclosure was made in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 Investors should monitor the company's next appointment for this role to ensure continuity in the formulation business segment. No immediate portfolio changes are recommended based on this routine management exit.

Alembic Pharma Receives USFDA Final Approval for Paroxetine ER Tablets (12.5 mg)

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 27 Mar 2026, 03:19 PM

Alembic Pharmaceuticals has received final USFDA approval for its supplemental Abbreviated New Drug Application (sANDA) for Paroxetine Extended-Release Tablets, 12.5 mg. This product is therapeutically equivalent to Paxil CR Tablets and is used to treat major depressive and anxiety disorders. This approval strengthens Alembic's US portfolio, bringing its cumulative total to 235 ANDA approvals, including 216 final approvals. The approval allows the company to expand its presence in the central nervous system (CNS) therapeutic segment in the US market.

Received final USFDA approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
Product is therapeutically equivalent to the reference listed drug Paxil CR Tablets (Apotex Inc.)
Indicated for Major depressive disorder (MDD), Panic disorder (PD), and Social anxiety disorder (SAD)
Cumulative USFDA approvals now stand at 235 (216 final and 19 tentative approvals)

💡 This approval is a positive development for Alembic's US generics business. Investors should monitor the company's product launch timeline and its ability to capture market share in the competitive CNS drug category.

Alembic Pharma to Close Trading Window from April 1, 2026, for Q4 and FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Mar 2026, 03:09 PM

Alembic Pharmaceuticals Limited has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is a standard procedure preceding the declaration of the company's audited financial results for the quarter and financial year ending March 31, 2026. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are made public. The specific date for the board meeting to approve these results will be announced by the company at a later date.

Trading window closure to commence on April 1, 2026.
Closure is related to the audited financial results for the quarter and year ending March 31, 2026.
Window will reopen 48 hours after the official declaration of financial results.
Compliance follows SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory announcement with no impact on business fundamentals. Investors should look out for the upcoming board meeting date to prepare for the Q4 and FY26 earnings release.

Alembic Pharmaceuticals to Meet Nomura Holdings on March 24, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 20 Mar 2026, 11:41 AM

Alembic Pharmaceuticals Limited (APLLTD) has scheduled a one-on-one meeting with institutional investor Nomura Holdings. The meeting is slated for Tuesday, March 24, 2026, and will be conducted via video conferencing. This disclosure is a routine regulatory requirement under SEBI listing obligations regarding interactions with institutional investors. No specific financial targets or material business changes were announced in this scheduling notification.

One-on-one investor meeting scheduled with Nomura Holdings.
Interaction date set for March 24, 2026.
Meeting to be conducted through Video Conferencing mode.
Routine disclosure as per SEBI (Listing Obligations and Disclosure Requirements) Regulations.

💡 No immediate action is required as this is a routine administrative disclosure. Investors may monitor the exchange filings for any post-meeting presentations or transcripts that might provide insights into the company's future outlook.

Alembic Pharmaceuticals Incorporates New Subsidiary in Thailand for Market Expansion

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 09 Mar 2026, 07:51 PM

Alembic Pharmaceuticals Limited has successfully incorporated a new subsidiary, Alembic Pharmaceuticals (Thailand) Co., Ltd., in Thailand. The company holds a 99.99% stake in the new entity, which has an initial share capital of 3,000,000 Baht. This strategic move is designed to explore new business opportunities and facilitate the promotion, sale, and distribution of pharmaceutical products within the Thai geography. While the subsidiary has yet to commence operations, it marks a clear intent to strengthen the company's international presence.

Incorporation of Alembic Pharmaceuticals (Thailand) Co., Ltd. as a 99.99% owned subsidiary
Initial share capital of 3,000,000 Baht divided into 300,000 shares of 10 Baht each
Primary objective is to promote and distribute pharmaceutical products in the Thailand market
Current turnover is nil as the entity is newly incorporated and yet to start operations
Investment is made in cash for the acquisition of share capital

💡 Investors should monitor the company's progress in the Southeast Asian market as this expansion could provide a new revenue stream. No immediate action is required as the financial impact will only be visible once operations commence.

Alembic Pharma Reports First US Prescription Sale of Branded Antibiotic Pivya®

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 06 Mar 2026, 09:05 AM

Alembic Pharmaceuticals has achieved its first prescription sale of Pivya® in the US, marking its official entry into the US branded specialty market. Pivya® is a first-line antibiotic for uncomplicated urinary tract infections (uUTIs), a therapeutic category with approximately 30 million prescriptions annually in the US. This launch follows a strategic acquisition and represents a shift from a purely generic-focused model to a branded specialty portfolio in the US. The company has established an initial sales footprint and plans a phased expansion of its field force to drive growth.

First prescription sale of Pivya® in the US, marking Alembic's first branded product launch in the region.
Targets the uUTI market in the US, which accounts for approximately 30 million prescriptions annually.
Marketed through Alembic Therapeutics LLC, a step-down wholly owned subsidiary of the company.
Represents a strategic shift to build a branded specialty portfolio alongside its established generics business.
Initial sales footprint established across key US territories with plans for phased field force expansion.

💡 Investors should monitor the prescription growth and market penetration of Pivya® as it represents a higher-margin opportunity compared to traditional generics. This strategic entry into the US branded market could be a long-term value driver for the stock.

View All APLLTD Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 7% YoY to INR 6,672 Cr in FY25. For H1 FY26, revenue increased 13% YoY to INR 3,621 Cr. The India Branded Business grew 5% YoY in Q2 FY26 to INR 639 Cr. International generic business showed healthy growth, while the API business experienced a decline in FY25 but is expected to recover.

Geographic Revenue Split

The company has a significant presence in the US market, which is expected to grow by at least 10% per annum over FY26-FY27. Other key markets include Canada, Chile, the European Union, and Australia, with strategic alliances strengthened in Australia and Europe through new product launches.

Profitability Margins

Gross margins are guided to remain in the 70-75% range. The PAT margin stood at 9% in FY25. Operating margins are expected to improve to 16-17% over the medium term as capacity utilization of new facilities increases.

EBITDA Margin

EBITDA margin improved to 16% in FY25 from 15% in FY24, representing a 10% growth in absolute EBITDA to INR 1,053 Cr. H1 FY26 EBITDA margin (post-R&D) was 17% (INR 613 Cr), reflecting improved capacity utilization and revenue growth.

Capital Expenditure

The company has completed its major capital expenditure cycle for three new manufacturing facilities. Annual cash accruals of INR 700-800 Cr are expected to be sufficient to cover routine maintenance capex and working capital requirements.

Credit Rating & Borrowing

Credit ratings are maintained with a 'Stable' outlook. Total debt increased to INR 1,258 Cr as of March 31, 2025, from INR 513 Cr in the previous year due to higher working capital needs. Interest costs for Q2 FY26 rose to INR 76 Cr from INR 71 Cr YoY.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) and specialty chemicals used in complex chemistry formulations; specific chemical names not disclosed.

Capacity Expansion

The company has three new manufacturing facilities targeted at the US market, all of which are USFDA approved. Commercial operations began in H2 FY23 and FY24. Current focus is on ramping up utilization to achieve economies of scale.

Raw Material Costs

Raw material costs are managed through a focus on high-margin projects and cost optimization measures to maintain gross margins above 70%.

Manufacturing Efficiency

Capacity utilization is currently sub-optimal at new facilities, resulting in an overhead absorption impact of approximately INR 150 Cr in FY25, which constrained profitability.

📈 Strategic Growth

Expected Growth Rate

10-11%

Growth Strategy

Growth will be driven by ramping up three new USFDA-approved facilities, launching 15-20 new products in the US market in FY26, and focusing on complex chemistry and specialty therapies like Entresto and Pivya. The company is shifting its portfolio mix toward higher-margin specialty products to enhance profitability.

Products & Services

Differentiated generics, specialty therapies, branded formulations, and Active Pharmaceutical Ingredients (APIs).

Brand Portfolio

Alembic Pharmaceuticals.

New Products/Services

Planned launch of 15-20 products in the US market in FY26. Recent launches include Pivya and Entresto generics.

Market Expansion

Expanding geographic presence in the US, Canada, Chile, EU, and Australia.

Strategic Alliances

Strategic alliances with partners in Australia and Europe for new product launches; acquisition of Utility Therapeutics to support the Pivya launch.

🌍 External Factors

Industry Trends

The industry is seeing growing penetration of health insurance and a shift toward complex generics. Alembic is positioning itself by investing in R&D for difficult-to-formulate molecules that generate superior value.

Competitive Landscape

Intense competition in the US generic space and domestic acute therapy segments.

Competitive Moat

Moat is built on a strong ANDA pipeline (220 cumulative approvals), USFDA-approved manufacturing infrastructure, and expertise in complex chemistry. These are sustainable due to high entry barriers in specialty generics.

Macro Economic Sensitivity

Margins are sensitive to inflation-driven costs and pricing pressure in international markets.

Consumer Behavior

Increased demand for specialty therapies and chronic disease treatments.

Geopolitical Risks

Exposure to regulatory changes in India and overseas markets (US, EU, Australia).

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA, European Medicines Agency (EMA), and TGA Australia inspections. Domestic operations are impacted by the Drug Pricing Control Order (DPCO).